Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Decera Clinical Education Oncology Podcast

Decera Clinical Education Oncology Podcast artwork

H3 K27M–Mutated Diffuse Midline Glioma: Bridging Molecular Pathology and Clinical Care

Nov 13, 202641 minAudioEpisode 280
ShareXLinkedInFacebookWhatsAppEmail

In this podcast episode, Craig Horbinski, MD, PhD, and Michael W. Ruff, MD, discuss the evolving diagnosis and management of H3 K27-altered diffuse midline glioma (DMG), emphasizing the importance of molecular testing, multidisciplinary collaboration, and emerging therapeutic strategies, including: The molecular and epigenetic characteristics of H3 K27-altered DMG and their implications for tumor classification and diagnosis Challenges in distinguishing DMG from other brainstem lesions and the importance of tissue biopsy, molecular profiling, and integrated pathology reporting Emerging diagnostic approaches, including cerebrospinal fluid analysis, cell-free DNA testing, and epigenomic profiling Current treatment strategies and emerging therapies, including radiotherapy, dordaviprone, and investigational CAR T-cell therapies The role of tissue stewardship, multidisciplinary coordination, and postmortem research in advancing diagnosis, selecting treatment, and understanding therapeutic response Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Craig Horbinski, MD, PhD Chair Professor and Clinician Investigator of Pathology Department of Laboratory Medicine and Pathology Mayo Clinic Florida Vice Chair, Translational Research, Neuro-Oncology Committee Alliance for Clinical Trials in Oncology Jacksonville, Florida Michael W. Ruff, MD Assistant Professor of Neurology and Medical Oncology Mayo Clinic Rochester, Minnesota Link to full program: https://bit.ly/4iPzgQh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Hematologist On Call: Relapsed/Refractory Mantle Cell Lymphoma Post cBTKi

    Nov 5, 202627 minAudio

    In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line...

    Credit the people on this episode

  2. Rethinking MZL: From Established Options to T-Cell–Directed Therapies

    Nov 4, 202630 minAudio

    This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell-engaging approaches for...

    Credit the people on this episode

  3. TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies

    Oct 29, 202629 minAudio

    In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including: Current clinical use of Dato-DXd in previously treated...

    Credit the people on this episode

  4. Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma

    Oct 19, 202624 minAudio

    In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including: Selecting quadruplet therapy Optimal use of bortezomib The role of autologous...

    Credit the people on this episode

  5. PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management

    Oct 9, 202627 minAudio

    In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify...

    Credit the people on this episode